The history of copyright's flagship drug presents a nuanced case for investors in the medicinal sector. While initially a phenomenal success, producing billions, the exclusivity end and the subsequent flood of cheaper competitors have drastically impacted income. This raises questions about the long-term viability of similar therapeutic development